The emerging role of imaging in prostate cancer secondary screening: Multiparametric magnetic resonance imaging and the incipient incorporation of molecular imaging

Javad Azadi, My Linh Nguyen, Antione Leroy, Katarzyna J. Macura, Michael A. Gorin, Steven P. Rowe

Research output: Contribution to journalReview articlepeer-review

Abstract

An increasingly robust body of evidence indicates that multiparametric MRI (mpMRI) prior to prostate biopsy can improve the detection of clinically significant prostate cancer while avoiding unnecessary biopsies. As a result, the use of mpMRI and biopsy platforms that allow for the real-time fusion of mpMRI and transrectal ultrasound images is now routinely used in clinical practice. On the horizon, molecular imaging offers the promise of improved sensitivity relative to mpMRI and early data would suggest that the combination of mpMRI and positron emission tomography using radiotracers targeting prostate-specific membrane antigen provide a more accurate assessment than either modality alone. In this review, we examine the current role of imaging to aid in the initial diagnosis of prostate cancer.

Original languageEnglish (US)
Article number20170960
JournalBritish Journal of Radiology
Volume91
Issue number1090
DOIs
StatePublished - 2018

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'The emerging role of imaging in prostate cancer secondary screening: Multiparametric magnetic resonance imaging and the incipient incorporation of molecular imaging'. Together they form a unique fingerprint.

Cite this